Healthcare Services

Central Nervous System (CNS) Lymphoma Market Expected to Record Steady Growth and Approach $2.08 Billion by 2030

March 31, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Value Is Expected For The Central Nervous System (CNS) Lymphoma Market At The End Of The 2026–2030 Forecast Period?

The market for central nervous system (cns) lymphoma has experienced significant expansion in recent years. It is forecast to increase from $1.53 billion in 2025 to $1.63 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.6%. This historical development can be credited to enhanced precision in lymphoma diagnosis, a rise in the application of high-dose chemotherapy protocols, the broadening of hospital oncology infrastructure, progress in neuro-oncology investigations, and the increasing supply of corticosteroid therapies.

The central nervous system (cns) lymphoma market size is projected to experience significant expansion in the upcoming years. It is expected to reach $2.09 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.4%. This growth during the forecast period can be attributed to increased investments in targeted oncology drugs, a rising uptake of personalized cancer treatments, the broadening of biomarker-driven therapy selection, a heightened focus on rare cancer research, and intensified clinical trial activities in cns malignancies. Major trends foreseen in the forecast period include the increasing adoption of targeted immunotherapy treatments, a rising application of monoclonal antibody-based therapies, greater integration of precision diagnostics in treatment planning, the expansion of combination therapy approaches, and an enhanced emphasis on early disease detection.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21133&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Central Nervous System (CNS) Lymphoma Market?

The central nervous system (CNS) lymphoma market is projected to grow, driven by the rising occurrences of psychological disorders. These conditions represent mental health issues that interfere with an individual’s thoughts, feelings, or actions, leading to distress or reduced functioning. Factors contributing to this increase include stress, social isolation, economic pressures, genetic predispositions, substance abuse, and excessive digital use. Research into central nervous system (CNS) lymphoma furthers neuro-oncology by enhancing comprehension of brain inflammation, immune system interactions, and the blood-brain barrier, which, in turn, assists in creating more effective treatments for both cancer and psychological disorders. An example from November 2023 by the UK’s National Health Service revealed that in 2023, an estimated one in five individuals aged 8 to 25 years had a probable mental disorder, impacting 20.3% of 8 to 16-year-olds, 23.3% of 17 to 19-year-olds, and 21.7% of 20 to 25-year-olds. Thus, the rising frequency of psychological disorders is a significant catalyst for the central nervous system (CNS) lymphoma market’s expansion.

What Segment Types Make Up The Central Nervous System (CNS) Lymphoma Market?

The central nervous system (cns) lymphoma market covered in this report is segmented –

1) By Class Of Drugs: Monoclonal Antibodies, Chemotherapeutic Agents, Corticosteroids

2) By Treatment: Chemotherapy, Radiation Therapy, Steroid Therapy, Targeted Therapy

3) By Application: Hospitals, Clinics, Ambulatory Surgical Services, Other Applications

Subsegments:

1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies, Anti-PD-1 Monoclonal Antibodies, Other Targeted Monoclonal Antibodies

2) By Chemotherapeutic Agents: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors

3) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone

Which Trends Are Impacting The Growth Of The Central Nervous System (CNS) Lymphoma Market?

Leading companies in the central nervous system (CNS) lymphoma market are prioritizing the development of innovative treatments such as Tirabrutinib for addressing primary central nervous system (CNS) lymphoma. Tirabrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor designed to treat B-cell malignancies, including primary central nervous system lymphoma (PCNSL), by targeting pathways essential for cancer cell survival and proliferation. For instance, in March 2023, ONO Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to tirabrutinib (ONO-4059) for the treatment of primary central nervous system lymphoma (PCNSL). This compound, a potent and selective BTK inhibitor targeting B-cell proliferation and survival, is presently under investigation in the phase 2 PROSPECT study (NCT04947319). Tirabrutinib works by regulating cellular proliferation and activation through the B-cell receptor, which promotes the survival, differentiation, and clonal expansion of B-cells.

Who Are The Key Players Driving Competition In The Central Nervous System (CNS) Lymphoma Market?

Major companies operating in the central nervous system (cns) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis International AG, Takeda Pharmaceutical Company Limited, Amgen Inc., Incyte Corporation, Kazia Therapeutics Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc., Bristol‑Myers Squibb Company, Johnson & Johnson, AstraZeneca plc, Pfizer Inc, BeiGene Ltd, Bayer AG, Spectrum Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, Kyowa Kirin Co Ltd, Celltrion Inc, Regeneron Pharmaceuticals Inc, BioNTech SE, PIQUR Therapeutics AG, Curis Inc, TG Therapeutics Inc, Oncoceutics Inc, XEME Biopharma LLC

Read the full central nervous system (cns) lymphoma market report here:

https://www.thebusinessresearchcompany.com/report/central-nervous-system-cns-lymphoma-global-market-report

Which Regions Are Projected To Dominate The Central Nervous System (CNS) Lymphoma Market In The Coming Years?

North America was the largest region in the central nervous system (CNS) lymphoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system (cns) lymphoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Central Nervous System (CNS) Lymphoma Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21133&type=smp

Browse Through More Reports Similar to the Global Central Nervous System (CNS) Lymphoma Market 2026, By The Business Research Company

Lab Supplies Global Market Report

https://www.thebusinessresearchcompany.com/report/lab-supplies-global-market-report

Medical And Diagnostic Laboratory Services Global Market Report

https://www.thebusinessresearchcompany.com/report/medical-and-diagnostic-laboratory-services-global-market-report

Laboratory Testing Services Global Market Report

https://www.thebusinessresearchcompany.com/report/laboratory-testing-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795